Five documented deliverables in 3–5 weeks. Risk Mapping Matrix (RPN), Decision Architecture Map, CDMO Capability Envelope, Specification Gap Map, Executive Technical Summary. Peptide-only. No execution liability.
Executive Technical Summary. Risk Mapping Matrix FMEA RPN. Decision Architecture Map. Supplier Qualification Framework Capability Envelope. Documentation and Specification Gap Map. ICH Q9 methodology. Tech transfer readiness. GMP track record.
Explicit scope boundaries for pre-CDMO peptide CMC work. What Bion Labs maps, what remains with the sponsor, and what is never touched. Tier A fixed scope.
Pre-CDMO Decision Architecture. Risk Mapping RPN Methodology. CDMO Qualification Logic. Specification and Documentation Gap Assessment. Tech Transfer Readiness Review. Governance Layer During CDMO Engagement. No manufacturing. No CDMO brokerage. No execution management. No regulatory submissions. Peptide-only.
Bion Labs peptide CMC engagement process. Structured workflow from initial contact through Tier A deliverables and optional Tier B governance. Pre-CDMO decision architecture methodology.
Initial technical conversation. Program assessment. Risk mapping. Decision architecture. CDMO capability envelope. Specification gap analysis. Documented deliverables. Tier B governance option.
Bion Labs is a peptide-only technical partner for early-stage biotech. Pre-CDMO decision architecture, risk mapping, and CDMO qualification governance. The decision is the risk problem.
Peptide CMC governance. Early-stage biotech. IND-enabling timelines. CDMO selection risk. Specification architecture. Irreversible decisions. No manufacturing. No brokerage. No financial interest in CDMO selection.
Manufacturing readiness assessment for peptide programs approaching CDMO engagement. Evaluate process definition, analytical methods, documentation, and tech transfer preparedness.
Process definition maturity. Analytical method validation. Raw material qualification. Specification integrity. Scale-up risk factors. Tech transfer documentation. GMP readiness indicators. CMC decision architecture.
Structured CDMO qualification framework for peptide programs. Capability envelope assessment covering synthesis, purification, analytical methods, and GMP track record.
CDMO capability vs capacity. Purification capability mapping. Analytical method alignment. Tech transfer readiness. GMP track record assessment. Risk-ranked CDMO shortlist. Qualification criteria per program. Peptide-specific supplier evaluation.
Five documented deliverables in 3–5 weeks. Risk Mapping Matrix with RPN scoring, Decision Architecture Map, CDMO Capability Envelope, Specification Gap Map, and Executive Technical Summary. Peptide-only. No execution liability. Tier A fixed-scope engagement for early-stage biotech navigating CDMO selection.
Pre-CDMO decision architecture. ICH Q9 risk methodology. FMEA risk priority number. CDMO qualification logic. Specification gap analysis. Tech transfer readiness review. GMP track record assessment. Peptide CMC governance.
Structured traceability systems for peptide programs approaching GMP manufacturing. Batch records, standard operating procedures, change control infrastructure, deviation management, and version-controlled documentation architecture.
Batch record traceability. SOP version control. Change control documentation. Deviation management systems. Audit readiness assessment. GMP documentation infrastructure. Lot genealogy tracking. Raw material traceability. Peptide manufacturing documentation governance.